ID   ERG1_RAT                Reviewed;         573 AA.
AC   P52020; Q4V8L3;
DT   01-OCT-1996, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-1996, sequence version 1.
DT   02-OCT-2024, entry version 152.
DE   RecName: Full=Squalene monooxygenase;
DE            EC=1.14.14.17 {ECO:0000269|PubMed:17112472, ECO:0000269|PubMed:7814369};
DE   AltName: Full=Squalene epoxidase {ECO:0000303|PubMed:7814369};
DE            Short=SE {ECO:0000303|PubMed:7814369};
GN   Name=Sqle; Synonyms=Erg1;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, CATALYTIC ACTIVITY, PATHWAY, ACTIVITY
RP   REGULATION, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RC   TISSUE=Kidney;
RX   PubMed=7814369; DOI=10.1074/jbc.270.1.17;
RA   Sakakibara J., Watanabe R., Kanai Y., Ono T.;
RT   "Molecular cloning and expression of rat squalene epoxidase.";
RL   J. Biol. Chem. 270:17-20(1995).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Placenta;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [3]
RP   FUNCTION, CATALYTIC ACTIVITY, COFACTOR, BIOPHYSICOCHEMICAL PROPERTIES, AND
RP   MUTAGENESIS OF TYR-194; TYR-209; PHE-223; PHE-228; PHE-287; PHE-305;
RP   TYR-334; TYR-473; PHE-476; PHE-491; PHE-522; PHE-523 AND TYR-528.
RX   PubMed=17112472; DOI=10.1016/j.bbrc.2006.11.014;
RA   Abe I., Abe T., Lou W., Masuoka T., Noguchi H.;
RT   "Site-directed mutagenesis of conserved aromatic residues in rat squalene
RT   epoxidase.";
RL   Biochem. Biophys. Res. Commun. 352:259-263(2007).
CC   -!- FUNCTION: Catalyzes the stereospecific oxidation of squalene to (S)-
CC       2,3-epoxysqualene, and is considered to be a rate-limiting enzyme in
CC       steroid biosynthesis. {ECO:0000269|PubMed:17112472,
CC       ECO:0000269|PubMed:7814369}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=O2 + reduced [NADPH--hemoprotein reductase] + squalene = (S)-
CC         2,3-epoxysqualene + H(+) + H2O + oxidized [NADPH--hemoprotein
CC         reductase]; Xref=Rhea:RHEA:25282, Rhea:RHEA-COMP:11964, Rhea:RHEA-
CC         COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379,
CC         ChEBI:CHEBI:15440, ChEBI:CHEBI:15441, ChEBI:CHEBI:57618,
CC         ChEBI:CHEBI:58210; EC=1.14.14.17;
CC         Evidence={ECO:0000269|PubMed:17112472, ECO:0000269|PubMed:7814369};
CC   -!- COFACTOR:
CC       Name=FAD; Xref=ChEBI:CHEBI:57692;
CC         Evidence={ECO:0000269|PubMed:17112472};
CC   -!- ACTIVITY REGULATION: Inhibited by NB-598 ((E)N-ethyl-N-(6,6-dimethyl-2-
CC       hepten-4-ynyl)-3-[(3,3'-bi-thiophen-5-yl)methoxy]benzene-methanamine).
CC       Contrary to fungal enzymes, the mammalian enzyme is only slightly
CC       inhibited by terbinafine. {ECO:0000269|PubMed:7814369}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=9.87 uM for squalene {ECO:0000269|PubMed:17112472};
CC   -!- PATHWAY: Terpene metabolism; lanosterol biosynthesis; lanosterol from
CC       farnesyl diphosphate: step 2/3. {ECO:0000305|PubMed:7814369}.
CC   -!- SUBUNIT: Interacts (via N-terminal domain) with MARCHF6. Interacts with
CC       SMIM22; this interaction modulates lipid droplet formation.
CC       {ECO:0000250|UniProtKB:Q14534}.
CC   -!- SUBCELLULAR LOCATION: Microsome membrane {ECO:0000269|PubMed:7814369};
CC       Peripheral membrane protein {ECO:0000250|UniProtKB:Q14534}. Endoplasmic
CC       reticulum membrane; Peripheral membrane protein
CC       {ECO:0000250|UniProtKB:Q14534}.
CC   -!- TISSUE SPECIFICITY: Detected in lever (at protein level).
CC       {ECO:0000269|PubMed:7814369}.
CC   -!- DOMAIN: The C-terminal hydrophobic region contains two helices that
CC       mediate interaction with membranes. Contrary to predictions, this
CC       region does not contain transmembrane helices.
CC       {ECO:0000250|UniProtKB:Q14534}.
CC   -!- DOMAIN: The N-terminal region mediates interaction with MARCHF6,
CC       leading to SQLE ubiquitination and proteasomal degradation when
CC       cholosterol levels are high. The first part of the N-terminal region
CC       contains a hydrophobic region that inserts into the membrane; contrary
CC       to predictions, there are no transmembrane helices. The second part
CC       contains a region that can form an amphipathic region that associates
CC       with membranes. This region is ejected from the membrane by high
CC       cholesterol levels and becomes disordered in an aqueous environment.
CC       This is critical for cholesterol-dependent proteasomal degradation.
CC       Additional parts of the N-terminal region are predicted to be
CC       disordered and contribute to flagging the protein for proteasomal
CC       degradation already under basal conditions.
CC       {ECO:0000250|UniProtKB:Q14534}.
CC   -!- PTM: Ubiquitinated by MARCHF6 in response to high cholesterol levels in
CC       intracellular membranes, leading to proteasomal degradation.
CC       {ECO:0000250|UniProtKB:Q14534}.
CC   -!- SIMILARITY: Belongs to the squalene monooxygenase family.
CC       {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; D37920; BAA07141.1; -; mRNA.
DR   EMBL; BC097330; AAH97330.1; -; mRNA.
DR   PIR; A55767; A55767.
DR   RefSeq; NP_058832.1; NM_017136.2.
DR   AlphaFoldDB; P52020; -.
DR   SMR; P52020; -.
DR   STRING; 10116.ENSRNOP00000012883; -.
DR   BindingDB; P52020; -.
DR   ChEMBL; CHEMBL4241; -.
DR   DrugCentral; P52020; -.
DR   PhosphoSitePlus; P52020; -.
DR   jPOST; P52020; -.
DR   PaxDb; 10116-ENSRNOP00000012883; -.
DR   Ensembl; ENSRNOT00000012883.5; ENSRNOP00000012883.2; ENSRNOG00000009550.8.
DR   Ensembl; ENSRNOT00065003139; ENSRNOP00065002145; ENSRNOG00065002388.
DR   Ensembl; ENSRNOT00065007206; ENSRNOP00065004986; ENSRNOG00065004951.
DR   GeneID; 29230; -.
DR   KEGG; rno:29230; -.
DR   UCSC; RGD:3755; rat.
DR   AGR; RGD:3755; -.
DR   CTD; 6713; -.
DR   RGD; 3755; Sqle.
DR   eggNOG; KOG1298; Eukaryota.
DR   GeneTree; ENSGT00390000011759; -.
DR   HOGENOM; CLU_026390_0_0_1; -.
DR   InParanoid; P52020; -.
DR   OMA; AKRTFYW; -.
DR   OrthoDB; 148348at2759; -.
DR   PhylomeDB; P52020; -.
DR   TreeFam; TF331056; -.
DR   Reactome; R-RNO-191273; Cholesterol biosynthesis.
DR   SABIO-RK; P52020; -.
DR   UniPathway; UPA00767; UER00752.
DR   PRO; PR:P52020; -.
DR   Proteomes; UP000002494; Chromosome 7.
DR   Bgee; ENSRNOG00000009550; Expressed in duodenum and 20 other cell types or tissues.
DR   GO; GO:0005783; C:endoplasmic reticulum; IBA:GO_Central.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0043231; C:intracellular membrane-bounded organelle; ISO:RGD.
DR   GO; GO:0016020; C:membrane; ISS:UniProtKB.
DR   GO; GO:0071949; F:FAD binding; ISS:UniProtKB.
DR   GO; GO:0004506; F:squalene monooxygenase activity; IDA:RGD.
DR   GO; GO:0008203; P:cholesterol metabolic process; IMP:RGD.
DR   GO; GO:0140042; P:lipid droplet formation; ISS:UniProtKB.
DR   GO; GO:0042127; P:regulation of cell population proliferation; ISS:UniProtKB.
DR   GO; GO:1904614; P:response to biphenyl; IDA:RGD.
DR   GO; GO:0016126; P:sterol biosynthetic process; ISS:UniProtKB.
DR   Gene3D; 3.50.50.60; FAD/NAD(P)-binding domain; 1.
DR   InterPro; IPR036188; FAD/NAD-bd_sf.
DR   InterPro; IPR013698; Squalene_epoxidase.
DR   InterPro; IPR040125; Squalene_monox.
DR   PANTHER; PTHR10835; SQUALENE MONOOXYGENASE; 1.
DR   PANTHER; PTHR10835:SF0; SQUALENE MONOOXYGENASE; 1.
DR   Pfam; PF08491; SE; 1.
DR   PRINTS; PR00420; RNGMNOXGNASE.
DR   SUPFAM; SSF51905; FAD/NAD(P)-binding domain; 1.
PE   1: Evidence at protein level;
KW   Endoplasmic reticulum; FAD; Flavoprotein; Lipid metabolism; Membrane;
KW   Microsome; Oxidoreductase; Reference proteome; Ubl conjugation.
FT   CHAIN           1..573
FT                   /note="Squalene monooxygenase"
FT                   /id="PRO_0000209840"
FT   TOPO_DOM        1..19
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000250|UniProtKB:Q14534"
FT   INTRAMEM        20..40
FT                   /evidence="ECO:0000250|UniProtKB:Q14534"
FT   TOPO_DOM        41..573
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000250|UniProtKB:Q14534"
FT   REGION          1..99
FT                   /note="Interaction with MARCHF6"
FT                   /evidence="ECO:0000250|UniProtKB:Q14534"
FT   REGION          61..72
FT                   /note="Required for degradation in response to high
FT                   membrane cholesterol levels"
FT                   /evidence="ECO:0000250|UniProtKB:Q14534"
FT   REGION          100..573
FT                   /note="Sufficient for catalytic activity"
FT                   /evidence="ECO:0000269|PubMed:17112472,
FT                   ECO:0000269|PubMed:7814369"
FT   REGION          515..573
FT                   /note="Hydrophobic; mediates interaction with membranes"
FT                   /evidence="ECO:0000250|UniProtKB:Q14534"
FT   BINDING         132..133
FT                   /ligand="FAD"
FT                   /ligand_id="ChEBI:CHEBI:57692"
FT                   /evidence="ECO:0000250|UniProtKB:Q14534"
FT   BINDING         152..153
FT                   /ligand="FAD"
FT                   /ligand_id="ChEBI:CHEBI:57692"
FT                   /evidence="ECO:0000250|UniProtKB:Q14534"
FT   BINDING         160
FT                   /ligand="FAD"
FT                   /ligand_id="ChEBI:CHEBI:57692"
FT                   /evidence="ECO:0000250|UniProtKB:Q14534"
FT   BINDING         233
FT                   /ligand="FAD"
FT                   /ligand_id="ChEBI:CHEBI:57692"
FT                   /evidence="ECO:0000250|UniProtKB:Q14534"
FT   BINDING         249
FT                   /ligand="FAD"
FT                   /ligand_id="ChEBI:CHEBI:57692"
FT                   /evidence="ECO:0000250|UniProtKB:Q14534"
FT   BINDING         407
FT                   /ligand="FAD"
FT                   /ligand_id="ChEBI:CHEBI:57692"
FT                   /evidence="ECO:0000250|UniProtKB:Q14534"
FT   BINDING         420
FT                   /ligand="FAD"
FT                   /ligand_id="ChEBI:CHEBI:57692"
FT                   /evidence="ECO:0000250|UniProtKB:Q14534"
FT   SITE            194
FT                   /note="Important for enzyme activity"
FT                   /evidence="ECO:0000250|UniProtKB:Q14534"
FT   MUTAGEN         194
FT                   /note="Y->A: Strongly decreased catalytic activity."
FT                   /evidence="ECO:0000269|PubMed:17112472"
FT   MUTAGEN         209
FT                   /note="Y->A: Nearly abolishes catalytic activity."
FT                   /evidence="ECO:0000269|PubMed:17112472"
FT   MUTAGEN         223
FT                   /note="F->A: Increased enzyme activity."
FT                   /evidence="ECO:0000269|PubMed:17112472"
FT   MUTAGEN         228
FT                   /note="F->A: Strongly decreased affinity for squalene."
FT                   /evidence="ECO:0000269|PubMed:17112472"
FT   MUTAGEN         287
FT                   /note="F->A: Decreased enzyme activity."
FT                   /evidence="ECO:0000269|PubMed:17112472"
FT   MUTAGEN         305
FT                   /note="F->A: Decreased enzyme activity."
FT                   /evidence="ECO:0000269|PubMed:17112472"
FT   MUTAGEN         334
FT                   /note="Y->A: Decreased enzyme activity."
FT                   /evidence="ECO:0000269|PubMed:17112472"
FT   MUTAGEN         473
FT                   /note="Y->A: Nearly abolishes enzyme activity."
FT                   /evidence="ECO:0000269|PubMed:17112472"
FT   MUTAGEN         476
FT                   /note="F->A: Decreased enzyme activity."
FT                   /evidence="ECO:0000269|PubMed:17112472"
FT   MUTAGEN         491
FT                   /note="F->A: Decreased enzyme activity."
FT                   /evidence="ECO:0000269|PubMed:17112472"
FT   MUTAGEN         522
FT                   /note="F->A: Decreased enzyme activity."
FT                   /evidence="ECO:0000269|PubMed:17112472"
FT   MUTAGEN         523
FT                   /note="F->A: Decreased enzyme activity."
FT                   /evidence="ECO:0000269|PubMed:17112472"
FT   MUTAGEN         528
FT                   /note="Y->A: Decreased enzyme activity."
FT                   /evidence="ECO:0000269|PubMed:17112472"
SQ   SEQUENCE   573 AA;  64024 MW;  55222C911E2B8777 CRC64;
     MWTFLGIATF TYFYKKCGDV TLANKELLLC VLVFLSLGLV LSYRCRHRNG GLLGRHQSGS
     QFAAFSDILS ALPLIGFFWA KSPPESEKKE QLESKRRRKE VNLSETTLTG AATSVSTSSV
     TDPEVIIIGS GVLGSALATV LSRDGRTVTV IERDLKEPDR ILGECLQPGG YRVLRELGLG
     DTVESLNAHH IHGYVIHDCE SRSEVQIPYP VSENNQVQSG VAFHHGKFIM SLRKAAMAEP
     NVKFIEGVVL RLLEEDDAVI GVQYKDKETG DTKELHAPLT VVADGLFSKF RKNLISNKVS
     VSSHFVGFIM KDAPQFKANF AELVLVDPSP VLIYQISPSE TRVLVDIRGE LPRNLREYMT
     EQIYPQIPDH LKESFLEACQ NARLRTMPAS FLPPSSVNKR GVLLLGDAYN LRHPLTGGGM
     TVALKDIKIW RQLLKDIPDL YDDAAIFQAK KSFFWSRKRS HSFVVNVLAQ ALYELFSATD
     DSLRQLRKAC FLYFKLGGEC LTGPVGLLSI LSPDPLLLIR HFFSVAVYAT YFCFKSEPWA
     TKPRALFSSG AILYKACSII FPLIYSEMKY LVH
//
